Namwiwat Medical PCLBKK:NAM -1.73%40 EV-to-FCF is -35.54 as of Jul. 07, 2026. GuruFocus rates BKK:NAM with a GF Score™ of 40/100 and a GF Value™ of ฿6.04 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 417 Medical Devices & Instruments companies, Namwiwat Medical PCL ranks worse than 239807.91% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Namwiwat Medical PCL's Enterprise Value is ฿2,314 Mil.
Namwiwat Medical PCL's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ฿-65 Mil. Therefore, Namwiwat Medical PCL's EV-to-FCF for today is -35.54.
The historical rank and industry rank for Namwiwat Medical PCL's EV-to-FCF or its related term are showing as below:
BKK:NAM'
s EV-to-FCF Range Over the Past 10 Years
Min: -558.65 Med: -36.84 Max: 103.54
Current: -35.33
During the past 6 years, the highest EV-to-FCF of Namwiwat Medical PCL was 103.54. The lowest was -558.65. And the median was -36.84.
BKK:NAM's EV-to-FCF is ranked worse than 100% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 23.16
vs BKK:NAM: -35.33
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Namwiwat Medical PCL (BKK:NAM) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Namwiwat Medical PCL's PE Ratio (TTM) for today is calculated as:
Namwiwat Medical PCL's share price for today is ฿3.40.
Namwiwat Medical PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.103.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Namwiwat Medical PCL EV-to-FCF Related Terms
Namwiwat Medical PCL EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Namwiwat Medical PCL's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Namwiwat Medical PCL's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Namwiwat Medical PCL EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Namwiwat Medical PCL's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Namwiwat Medical PCL's EV-to-FCF falls into.
Namwiwat Medical PCL's current Enterprise Value is ฿2,314 Mil.
Namwiwat Medical PCL's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿-65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Namwiwat Medical PCL (BKK:NAM) has a EV-to-FCF of -35.54 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Namwiwat Medical PCL and its competitors. According to the industry distribution chart, Namwiwat Medical PCL ranks #999999 out of 417 companies in the Medical Devices & Instruments industry.
Is Namwiwat Medical PCL's EV-to-FCF too high?
Namwiwat Medical PCL's current EV-to-FCF is -35.54. Based on the distribution chart, Namwiwat Medical PCL ranks #999999 out of 417 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Namwiwat Medical PCL has a GF Score™ of 40/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Namwiwat Medical PCL ranks #999999 out of 417 companies for EV-to-FCF. This places Namwiwat Medical PCL in the lower half of its industry. The industry median EV-to-FCF is 23.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.16, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Namwiwat Medical PCL and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Namwiwat Medical PCL's current EV-to-FCF is -35.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿6.04, compared to a current price of ฿3.40 — trading 43.7% below its estimated fair value. The current EV-to-FCF is -35.54. Namwiwat Medical PCL's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current EV-to-FCF is -35.54 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?
Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued.
The current stock price of ฿3.40 is trading 43.7% below its estimated GF Value™ of ฿6.04.
GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.
Key valuation signals for BKK:NAM:
EV-to-FCF: -35.54
GF Value™: ฿6.04 vs. price of ฿3.40 (43.7% below fair value)
No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
40GF Score
Get the complete analysis for BKK:NAM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NAM has been successfully added to your 
